Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amplyx Pharmaceuticals

http://amplyx.com/

Latest From Amplyx Pharmaceuticals

Antifungal Drug Sponsors Seek Clearer Regulatory Pathway, Less Burdensome Trials

Citing difficulties in conducting randomized trials, industry speakers call for a new way of thinking about the US FDA's substantial evidence standard for antifungal approvals under the LPAD route, as well as revisions to enrollment criteria and study endpoints.

Clinical Trials Rare Diseases

Finance Watch: Atea Pharmaceuticals Raises $215m For COVID-19 Antiviral

Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.

Financing Coronavirus COVID-19

Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Deals Business Strategies

Amplyx Cleared To Complete Phase II Study Of New Antifungal Class

Fosmanogepix, with safety and efficacy clearances to continue Phase II, could provide an IV-to-oral option for patients with potentially lethal Candida fungal infections.

Clinical Trials Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Other Names / Subsidiaries
    • Arix Bioscience plc
UsernamePublicRestriction

Register